PNAS publication: characterization of group 2 Influenza antibodies
December 11, 2013 - A common solution to group 2 influenza virus neutralization
Nature SciBX reviews D25 guided RSV vaccine study
November 14, 2013 - Science-Business eXchange published an article discussing the recent Science study that used AIMMs D25 anti RSV antibody for vaccine design.
Pre-fusion RSV Antibodies
November 4, 2013 - November 4 – AIMM Therapeutics announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved vaccine against RSV.
PLOS pathogens paper
October 11, 2013 - Infection of host tissues by Staphylococcus aureus and S. epidermidis requires an unusual family of staphylococcal adhesive proteins that contain long stretches of serine-aspartate dipeptide-repeats (SDR).
September 16, 2013 - AIMM Therapeutics acquired an Innovation Credit of € 2,9 million from the Dutch government for one of our R&D projects.
ERC Advanced Grant
August 13, 2013 - AIMMs CSO Hergen Spits received a prestigious ERC Advanced Grant from the European Research Council.
July 30, 2013 - AIMM wil present a Nature webcast on July 31.
Scientific advisory board strengthened with new high profile appointments
June 21, 2013 - Bob Löwenberg (Erasmus MC), John Mendelsohn (MD Anderson), and Hidde Ploegh (Whitehead Institute) to join AIMM Scientific advisory board.
Structure of AIMM’s lead antibody D25 binding revealed
April 25, 2013 - Today Science published the pre-fusion cristal of RSV in complex with AIMMs antibody D25.